Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 5326370, 9 pages
https://doi.org/10.1155/2017/5326370
Research Article

Identification of Significant Pathways Induced by PAX5 Haploinsufficiency Based on Protein-Protein Interaction Networks and Cluster Analysis in Raji Cell Line

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Correspondence should be addressed to Wei Huang; moc.qq@1507066982

Received 6 November 2016; Revised 23 January 2017; Accepted 30 January 2017; Published 21 February 2017

Academic Editor: Yudong Cai

Copyright © 2017 Jia Gu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. M. Christopher, C. G. Mullighan, X. Su et al., “Pax5 haploinsufficiency cooperates with BCR-ABL1 to induce acute lymphoblastic leukemia,” Blood, vol. 112, article 293, 2008. View at Google Scholar
  2. C. G. Mullighan, S. Goorha, I. Radtke et al., “Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia,” Nature, vol. 446, no. 7137, pp. 758–764, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Medvedovic, A. Ebert, H. Tagoh, and M. Busslinger, “Pax5: a master regulator of B cell development and leukemogenesis,” Advances in Immunology, vol. 111, pp. 179–206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. P. O'Brien, P. Morin Jr., R. J. Ouellette, and G. A. Robichaud, “The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease,” Cancer Research, vol. 71, no. 24, pp. 7345–7350, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Cobaleda, W. Jochum, and M. Busslinger, “Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors,” Nature, vol. 449, no. 7161, pp. 473–477, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. L. M. Heltemes-Harris, M. J. L. Willette, L. B. Ramsey et al., “Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acutelymphoblastic leukemia,” Journal of Experimental Medicine, vol. 208, no. 6, pp. 1135–1149, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Iacobucci, A. Lonetti, F. Paoloni et al., “The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. a report on behalf of the GIMEMA acute leukemia working party,” Haematologica, vol. 95, no. 10, pp. 1683–1690, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Kim, J. E. Choi, C. J. She et al., “PAX5 deletion is common and concurrently occurs with CDKN2A deletion in B-lineage acute lymphoblastic leukemia,” Blood Cells, Molecules, and Diseases, vol. 47, no. 1, pp. 62–66, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Liso, D. Capello, T. Marafioti et al., “Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte- predominant and classic Hodgkin lymphoma,” Blood, vol. 108, no. 3, pp. 1013–1020, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Gaidano, L. Pasqualucci, D. Capello et al., “Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma,” Blood, vol. 102, no. 5, pp. 1833–1841, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Montesinos-Rongen, D. Van Roost, C. Schaller, O. D. Wiestler, and M. Deckert, “Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation,” Blood, vol. 103, no. 5, pp. 1869–1875, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Bousquet, C. Broccardo, C. Quelen et al., “A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5,” Blood, vol. 109, no. 8, pp. 3417–3423, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Familiades, M. Bousquet, M. Lafage-Pochitaloff et al., “PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study,” Leukemia, vol. 23, no. 11, pp. 1989–1998, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Dang, L. Wei, J. De Ridder et al., “PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia,” Blood, vol. 125, no. 23, pp. 3609–3617, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. M. A. J. Prasad, J. Ungerbäck, J. Åhsberg et al., “Ebf1 heterozygosity results in increased DNA damage in pro-B cells and their synergistic transformation by Pax5 haploinsufficiency,” Blood, vol. 125, no. 26, pp. 4052–4059, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Pridans, M. L. Holmes, M. Polli et al., “Identification of Pax5 target genes in early B cell differentiation,” Journal of Immunology, vol. 180, no. 3, pp. 1719–1728, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. S. L. Nutt, S. Vambrie, P. Steinlein et al., “Independent regulation of the two Pax5 alleles during B-cell development,” Nature Genetics, vol. 21, no. 4, pp. 390–395, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Szklarczyk, A. Franceschini, M. Kuhn et al., “The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored,” Nucleic Acids Research, vol. 39, no. 1, pp. D561–D568, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software environment for integrated models of biomolecular interaction networks,” Genome Research, vol. 13, no. 11, pp. 2498–2504, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources,” Nature Protocols, vol. 4, no. 1, pp. 44–57, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Kanehisa, S. Goto, M. Furumichi, M. Tanabe, and M. Hirakawa, “KEGG for representation and analysis of molecular networks involving diseases and drugs,” Nucleic Acids Research, vol. 38, no. 1, pp. D355–D360, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. J. D. Sander and J. K. Joung, “CRISPR-Cas systems for editing, regulating and targeting genomes,” Nature Biotechnology, vol. 32, no. 4, pp. 347–350, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. S. L. Nutt, B. Heavey, A. G. Rolink, and M. Busslinger, “Commitment to the B-lymphoid lineage depends on the transcription factor Pax5,” Nature, vol. 401, no. 6753, pp. 556–562, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. W. F. Marzluff, P. Gongidi, K. R. Woods, J. Jin, and L. J. Maltais, “The human and mouse replication-dependent histone genes,” Genomics, vol. 80, no. 5, pp. 487–498, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Piscopo, G. Campisi, G. Colella et al., “H3 and H3.3 histone mRNA amounts and ratio in oral squamous cell carcinoma and leukoplakia,” Oral Diseases, vol. 12, no. 2, pp. 130–136, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Sakamoto, T. Nieta, Y. Kamikawa et al., “The assessment of cell proliferation during 9,10-dimethyl-1,2-benzanthracene-induced hamster tongue carcinogenesis by means of histone H3 mRNA in situ hybridization,” Medical Electron Microscopy, vol. 37, no. 1, pp. 52–61, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. M. D. Smith, E. Healy, V. Thompson, A. Morley, and J. L. Rees, “Use of in situ detection of histone mRNA in the assessment of epidermal proliferation: comparison with the Ki67 antigen and BrdU incorporation,” British Journal of Dermatology, vol. 132, no. 3, pp. 359–366, 1995. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Iwaya, T. Fukagawa, Y. Suzuki et al., “Contrasting expression patterns of histone mRNA and microRNA 760 in patients with gastric cancer,” Clinical Cancer Research, vol. 19, no. 23, pp. 6438–6449, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Rieswijk, S. M. H. Claessen, O. Bekers et al., “Aflatoxin B1 induces persistent epigenomic effects in primary human hepatocytes associated with hepatocellular carcinoma,” Toxicology, vol. 350-352, pp. 31–39, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Ryall, R. Krishnatry, A. Arnoldo et al., “Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma,” Acta Neuropathologica Communications, vol. 4, no. 1, 2016. View at Publisher · View at Google Scholar
  31. J. A. Han, J. Kim, and J. Kim, “Analysis of gene expression in cyclooxygenase-2-overexpressed human osteosarcoma cell lines,” Genomics & Informatics, vol. 12, no. 4, pp. 247–253, 2014. View at Publisher · View at Google Scholar
  32. H. Guan, Z. Dai, Y. Ma, Z. Wang, X. Liu, and X. Wang, “MicroRNA-101 inhibits cell proliferation and induces apoptosis by targeting EYA1 in breast cancer,” International Journal of Molecular Medicine, vol. 37, no. 6, pp. 1643–1651, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. X. Feng, S. Jia, T. A. Martin, and W. G. Jiang, “Regulation and involvement in cancer and pathological conditions of MAGI1, a tight junction protein,” Anticancer Research, vol. 34, no. 7, pp. 3251–3256, 2014. View at Google Scholar · View at Scopus
  34. S. H. Kim, J.-N. Ho, H. Jin et al., “Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines,” Investigative and Clinical Urology, vol. 57, no. 1, pp. 63–72, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Misri, S. Pandita, R. Kumar, and T. K. Pandita, “Telomeres, histone code, and DNA damage response,” Cytogenetic and Genome Research, vol. 122, no. 3-4, pp. 297–307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Yoshioka, Y. Atsumi, H. Nakagama, and H. Teraoka, “Development of cancer-initiating cells and immortalized cells with genomic instability,” World Journal of Stem Cells, vol. 7, no. 2, pp. 483–489, 2015. View at Publisher · View at Google Scholar
  37. A. Schebesta, S. McManus, G. Salvagiotto, A. Delogu, G. A. Busslinger, and M. Busslinger, “Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function,” Immunity, vol. 27, no. 1, pp. 49–63, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Ran, “The role of TLR4 in chemotherapy-driven metastasis,” Cancer Research, vol. 75, no. 12, pp. 2405–2410, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Maru, T. Tomita, A. Deguchi et al., “Drug targeting based on a new concept-targeting against TLR4 as an example,” Endocrine, Metabolic and Immune Disorders—Drug Targets, vol. 15, no. 2, pp. 83–87, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. W. Sang, C. Sun, C. Zhang et al., “MicroRNA-150 negatively regulates the function of CD4+ T cells through AKT3/Bim signaling pathway,” Cellular Immunology, vol. 306-307, pp. 35–40, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Youssef, C. Gillett, O. Agbaje, T. Crompton, and X. Montano, “Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: a potential novel prognostic marker for breast cancer,” Modern Pathology, vol. 27, no. 3, pp. 361–374, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Wang, X. Xu, F. Xu et al., “Combined expression of c-jun, c-fos, and p53 improves estimation of prognosis in oral squamous cell carcinoma,” Cancer Investigation, vol. 34, no. 8, pp. 393–400, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Xiang, J. Lu, C. Zhang et al., “Identification and quantification of total coumarins from Urtica dentata hand and its roles in promoting immune tolerance via TLR4-mediated dendritic cell immaturation,” Bioscience, Biotechnology and Biochemistry, vol. 77, no. 6, pp. 1200–1206, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Eguchi, Y. Sekiya, M. Suzuki, T. Yamamoto, and H. Matsui, “An oral Salmonella vaccine promotes the down-regulation of cell surface Toll-like receptor 4 (TLR4) and TLR2 expression in mice,” FEMS Immunology and Medical Microbiology, vol. 50, no. 3, pp. 300–308, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Bendfeldt, M. Benary, T. Scheel et al., “Stable IL-2 decision making by endogenous c-Fos amounts in peripheral memory T-helper cells,” Journal of Biological Chemistry, vol. 287, no. 22, pp. 18386–18397, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Macián, F. García-Cózar, S.-H. Im, H. F. Horton, M. C. Byrne, and A. Rao, “Transcriptional mechanisms underlying lymphocyte tolerance,” Cell, vol. 109, no. 6, pp. 719–731, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Paul-Samojedny, A. Pudełko, M. Kowalczyk et al., “Combination therapy with AKT3 and PI3KCA siRNA enhances the antitumor effect of temozolomide and carmustine in T98G glioblastoma multiforme cells,” BioDrugs, vol. 30, no. 2, pp. 129–144, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. V. Tsiperson, R. C. Gruber, M. F. Goldberg et al., “Suppression of inflammatory responses during myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis is regulated by AKT3 signaling,” Journal of Immunology, vol. 190, no. 4, pp. 1528–1539, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Yang, S. Li, B. Wang et al., “Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer,” Tumor Biology, vol. 37, no. 9, pp. 11645–11655, 2016. View at Publisher · View at Google Scholar
  50. K. Nakai, M. C. Hung, and H. Yamaguchi, “A perspective on anti-EGFR therapies targeting triple-negative breast cancer,” American Journal of Cancer Research, vol. 6, no. 8, pp. 1609–1623, 2016. View at Google Scholar
  51. F. Nakayama, K. Müller, A. Hagiwara, R. Ridi, M. Akashi, and V. Meineke, “Involvement of intracellular expression of FGF12 in radiation-induced apoptosis in mast cells,” Journal of Radiation Research, vol. 49, no. 5, pp. 491–501, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Nakayama, S. Umeda, T. Yasuda et al., “Cellular internalization of fibroblast growth factor-12 exerts radioprotective effects on intestinal radiation damage independently of FGFR signaling,” International Journal of Radiation Oncology Biology Physics, vol. 88, no. 2, pp. 377–384, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. S. O. Vozianov, V. I. Kashuba, V. M. Grygorenko et al., “Identification of a new diagnostic markers of prostatic cancer, using noti-microchips,” Klinichna Khirurhiia, no. 4, pp. 54–57, 2016. View at Google Scholar · View at Scopus
  54. A. A. Dmitriev, E. E. Rosenberg, G. S. Krasnov et al., “Identification of novel epigenetic markers of prostate cancer by NotI-microarray analysis,” Disease Markers, vol. 2015, Article ID 241301, 13 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. H.-P. Lin, C.-Y. Lin, C. Huo et al., “AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf & TSC1/TSC2,” Oncotarget, vol. 6, no. 29, pp. 27097–27112, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. C. Stottrup, T. Tsang, and Y. R. Chin, “Upregulation of AKT3 confers resistance to the AKT inhibitor MK2206 in breast cancer,” Molecular Cancer Therapeutics, vol. 15, no. 8, pp. 1964–1974, 2016. View at Publisher · View at Google Scholar
  57. Y. Nonomiya, K. Noguchi, N. Tanaka, T. Kasagaki, K. Katayama, and Y. Sugimoto, “Effect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells,” Cancer Science, vol. 107, no. 12, pp. 1877–1887, 2016. View at Publisher · View at Google Scholar